You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 11, 2024

CLINICAL TRIALS PROFILE FOR DARUSENTAN


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Darusentan

Trial ID Title Status Sponsor Phase Summary
NCT00330369 ↗ DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension Completed Gilead Sciences Phase 3 This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension, despite treatment with full doses of three or more antihypertensive drugs, including a diuretic.
NCT00353574 ↗ DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension Terminated Gilead Sciences Phase 3 This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan in subjects with resistant systolic hypertension despite treatment with full doses of three or more antihypertensive medications, including a diuretic.
NCT00364026 ↗ A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs Completed Gilead Sciences Phase 2 This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension, despite treatment with full doses of three or more blood pressure lowering drugs, including a diuretic.
NCT00389675 ↗ DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension Terminated Gilead Sciences Phase 3 This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan (optimized dose) as compared to an active control, administered orally.
NCT00389779 ↗ DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension Completed Gilead Sciences Phase 3 This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic and diastolic hypertension despite treatment with full doses of three or more antihypertensive drugs, including a diuretic. Subjects will be randomized to darusentan (optimized dose), an active comparator, or placebo, administered orally. The treatment period for this trial is 14 weeks.
NCT00738049 ↗ Darusentan Effect on PET Uptake Heterogeneity Completed Gilead Sciences Phase 2 The primary objective of this study is to test the hypothesis that myocardial perfusion heterogeneity, quantified by Markovian Homogeneity analysis of cardiac PET perfusion images, will improve in a quantitative manner after treatment with selective ETA receptor antagonist darusentan 100 mg per day for 2 weeks compared to baseline and post-treatment PET scans in clinically stable subjects with coronary atherosclerosis and/or risk factors.
NCT00738049 ↗ Darusentan Effect on PET Uptake Heterogeneity Completed K.Lance Gould Phase 2 The primary objective of this study is to test the hypothesis that myocardial perfusion heterogeneity, quantified by Markovian Homogeneity analysis of cardiac PET perfusion images, will improve in a quantitative manner after treatment with selective ETA receptor antagonist darusentan 100 mg per day for 2 weeks compared to baseline and post-treatment PET scans in clinically stable subjects with coronary atherosclerosis and/or risk factors.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Darusentan

Condition Name

Condition Name
Intervention Trials
Hypertension 5
Coronary Artery Disease 1
Endothelial Dysfunction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH
Intervention Trials
Hypertension 5
Myocardial Ischemia 1
Coronary Disease 1
Coronary Artery Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Darusentan

Trials by Country

Trials by Country
Location Trials
United States 111
Argentina 5
Brazil 4
France 3
Denmark 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State
Location Trials
Texas 5
North Carolina 4
Nevada 4
Michigan 4
Maine 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Darusentan

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase Trials
Phase 3 4
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase Trials
Completed 4
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Darusentan

Sponsor Name

Sponsor Name
Sponsor Trials
Gilead Sciences 6
K.Lance Gould 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type
Sponsor Trials
Industry 6
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.